Clin2
NCT07675629Possibly a fitNot yet recruiting

HIV vaccine safety and immune response study

HIV Prevention

Part of Infections clinical trials.

This study tests a new HIV vaccine in healthy, HIV-negative adults to see if it is safe and creates an immune response. The vaccine uses DNA and a protein to try to teach your body to fight HIV.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
126 people
Ages
18 years to 55 years
Study type
Interventional

Who can take part

  • You are 18 to 55 years old.
  • You are HIV-negative and in good general health.
  • You are willing to get HIV tests and counseling about reducing HIV risk.
  • You are at low risk for getting HIV and plan to stay low-risk during the study.
  • You are not pregnant or breastfeeding, and you use effective birth control if needed.
  • You have not received an HIV vaccine before.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06796686Recruiting· Phase 1
HIV vaccine safety and immune response study for healthy adults

This trial tests a new two-part HIV vaccine regimen in healthy adults without HIV. The goal is to see if it is safe and produces an immune response that could help prevent HIV.

San Francisco, California
NCT07390474Recruiting· Phase 1
HIV vaccine safety and immune response study for healthy adults

This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.

Atlanta, Georgia
NCT06205056Recruiting· Phase 1
HIV vaccine safety and immune response test

This trial tests a new combination HIV vaccine in healthy adults to see if it is safe and produces an immune response. If you are at low risk for HIV, you may help researchers learn more about future prevention strategies.

Kampala
NCT07757802Not yet recruiting· Phase 1
Testing an experimental HIV vaccine for safety in healthy adults

This study tests an experimental HIV vaccine that uses tiny particles and mRNA technology in healthy adults. If you qualify, you'll help researchers see if it's safe and if it triggers an immune response.

San Francisco, California
NCT06617091Recruiting· Phase 1
HIV vaccine trial for healthy adults with and without HIV

This trial tests an experimental HIV vaccine in healthy adults, including those living with HIV. The goal is to see if the vaccine is safe and prompts an immune response.

Mtubatuba, KwaZulu-Natal
NCT07769983Enrolling by invitation· Phase 1
HIV vaccine study for people on effective treatment

This study tests a new vaccine designed to help your immune system fight HIV better. It is for people with HIV who are already on effective antiretroviral therapy and have a well-controlled virus. The goal is to see if the vaccine is safe and boosts your body's natural defenses.

Bern, Canton of Bern

Hear when a new HIV Prevention trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.